Home/Filings/4/0001053310-22-000003
4//SEC Filing

KAY E GERALD 4

Accession 0001053310-22-000003

CIK 0001016504other

Filed

Nov 9, 7:00 PM ET

Accepted

Nov 10, 6:39 PM ET

Size

5.7 KB

Accession

0001053310-22-000003

Insider Transaction Report

Form 4
Period: 2022-11-09
KAY E GERALD
DirectorCEO and President10% Owner
Transactions
  • Award

    Stock Option (right to buy)

    2022-11-09+100,000100,000 total
    Exp: 2027-11-09Common Stock (100,000 underlying)
Footnotes (2)
  • [F1]The Exercise Price of the Stock Option will be 110% the closing prices of the Issuer's Common Stock on the fifth trading day after the filing of the Issuer's Quarterly Report on Form 10-Q for the period ended September 30, 2022, with the Securities and Exchange Commission.
  • [F2]The option vests and becomes exercisable in three equal annual installments with the first installment vesting on November 9, 2023.

Issuer

INTEGRATED BIOPHARMA INC

CIK 0001016504

Entity typeother

Related Parties

1
  • filerCIK 0001053310

Filing Metadata

Form type
4
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 6:39 PM ET
Size
5.7 KB